Role of platelet gene polymorphisms in ischemic pediatric stroke subtypes: a case-control study

Aim To assess the role of human platelet antigens (HPA), P-selectin gene (SELP) polymorphisms, and HPA and SELP haplotypes with factor V (FV) R506Q in ischemic pediatric stroke (IPS) subtypes: cerebral sinovenous thrombosis (CSVT), perinatal (PAIS), and childhood (CAIS) arterial ischemic stroke.

Methods This case-control study enrolled 150 children with confirmed IPS and 150 age- and sex-matched controls. FV R506Q and HPA-1 were genotyped with CVD StripAssay®, HPA-2 and HPA-3 with real-time polymerase chain reaction, SELP S290N, V599L, and T715P with high resolution melting analysis, and SELP N562D with sequence-specific polymerase chain reaction.

Results HPA-1b allele (odds ratio [OR] 2.75, 95% confidence interval [CI] 1.02-7.42, \( P = 0.048 \)) and HPA-1a2a3b (OR 5.46, 95% CI 1.51-19.76, \( P = 0.011 \)), HPA-1b2a3a (OR 7.00, 95% CI 1.25-39.13, \( P = 0.028 \)), and HPA-1b2b3a (OR 11.39, 95% CI 1.39-92.95, \( P = 0.024 \)) haplotypes increased the risk for CSVT. HPA-3b allele was significantly associated with 2-fold lower risk for PAIS (OR 0.49, 95% CI 0.26-0.89, \( P = 0.020 \)) and CAIS (OR 0.47, 95% CI 0.26-0.86, \( P = 0.014 \)) and non-significantly associated with increased risk for CSVT (OR 6.43, 95% CI 0.83-50.00, \( P = 0.022 \)). HPA-1a2b3a haplotype was significantly associated with CAIS (OR 6.76, 95% CI 2.13-21.44, \( P = 0.001 \)). The inclusion of FV R506Q in SELP haplotype analysis increased the risk for PAIS 4-fold in QNDVT carriers (OR 8.14, 95% CI 0.93-71.33, \( P = 0.060 \)) compared with NDVT haplotype (OR 2.45, 95% CI 0.98-6.18, \( P = 0.058 \)), but the result was not significant.

Conclusion Individual HPAs, and particularly HPA haplotypes, are involved in IPS subtypes pathogenesis. A possible risk-inducing synergistic effect of SELP haplotypes with FV R506Q is restricted to PAIS only.

Received: August 28, 2019
Accepted: January 10, 2020
Correspondence to: Renata Zadro
University Hospital Centre Zagreb
Department of Laboratory Diagnostics
Kišpatićeva 12
10000 Zagreb, Croatia
renata.zadro@mef.hr
Ischemic pediatric stroke (IPS) is a relatively rare heterogeneous multifactorial disorder caused by arterial (ie, arterial ischemic stroke, AIS) or venous occlusion (ie, cerebral sinovenous thrombosis, CSVT). According to the time of stroke onset, AIS is classified as perinatal (PAIS) and childhood AIS (CAIS) (1,2). IPS subtypes differ in incidence rates, etiology, presentation symptoms, and treatment strategies (2,3), and their predisposing disorders are still incompletely understood and characterized (4-6). Risk factors for IPS include various inherited and acquired prothrombotic disorders (2,4,5). However, the role of different genetic risk factors in the etiology of IPS subtypes has been studied in a limited number of publications, and studies including multiple genetic factors and haplotype analysis are extremely rare.

The most frequently investigated genetic risk factor is the polymorphism in factor V gene (FV) that causes amino acid change R506Q (FV Leiden, NM_000130.4:c.1601G>A, rs6025) and consequently activated protein C resistance and susceptibility to thrombosis (7). FV R506Q has been regularly associated with IPS, although in CSVT the association is weaker in children than in adults (4,8-10).

Platelets have a significant role in maintaining normal hemostasis. Changes in the structure of platelet membrane proteins can change platelet function and predisposition to thrombophilia. The effect of variations in platelet glycoprotein receptor genes and the P-selectin adhesion molecule on their role in IPS has not been established yet (11).

Human platelet antigens (HPA) are genetically defined polymorphisms expressed on platelet membrane glycoproteins. In three out of six biallelic systems, ie, HPA-1 (NM_000212.2:c.1767T>C, rs5918) on glycoprotein IIa, HPA-2 (NM_000093.5:c.482C>T, rs6065) on glycoprotein Iba, and HPA-3 (NM_000419.3:c.2621T>G, rs5911) on glycoprotein IIb, a base-pair substitution leads to amino acid change in a platelet surface membrane glycoprotein. These biallelic systems modulate platelet receptor density, altering platelet function and thrombus formation (12-14). The role of HPAs in ischemic stroke has been recognized, but poorly investigated in adults (15-18) and particularly in children (9,19-21).

P-selectin mediates the interaction of activated endothelial cells or platelets with leukocytes (22,23). Multiple polymorphisms in P-selectin gene (SELP) have been described, but only five of them cause amino acid substitution that may influence its function: V168M (NM_003005.3:c.625G>A, rs6125), S290N (NM_003005.3:c.992G>A, rs6131), N562D (NM_003005.3:c.1807G>A, rs6127), V599L (NM_003005.3:c.1918G>T, rs6133), and T715P (NM_003005.3:c.2266A>C, rs6136) (24). SELP polymorphisms appear to be associated with several stages of thrombosis and associated diseases, including venous thromboembolism and atherothrombotic disease (25-27), cardiovascular disease, and myocardial infarction in adults (24,28-31). Although the relationship of different SELP polymorphisms to ischemic stroke in adults has been described (32-37), there are no reports regarding their role in IPS.

Since IPS subtypes have different pathophysiologic backgrounds, it is justified to investigate the relative relationship between thrombophilia polymorphisms and stroke subtypes. Therefore, the aim of this study was to assess the role of eight individual polymorphisms (FV R506Q, HPA-1, HPA-2, HPA-3, SELP S290N, N562D, V599L, and T715P) and their haplotypes (HPA-1/-2/-3, SELP S290N/N562D/V599L/T715P, and FV R506Q /SELP S290N/N562D/V599L/T715P) in IPS subtypes: PAIS, CAIS, and CSVT.

**PARTICIPANTS AND METHODS**

**Participants**

This case-control study enrolled 150 children aged up to 18 years with a confirmed diagnosis of PAIS, CAIS, or CSVT and 150 age- and sex-matched controls from the same geographical region with no history of thromboembolic or neurological events and with normal C reactive protein levels. Controls were recruited among children undergoing minor surgery such as tonsillectomy and children with respiratory diseases at routine follow-up visits. All children were admitted to the University Hospital Centre Zagreb or Children's Hospital Zagreb, Zagreb, Croatia, from 1999 to 2018. The recruitment dynamics was five patients per year until 2004, with increasing tendency of seven to nine patients per year afterwards for AIS; one case of CSVT per year was recruited from 2008 to 2010 and three cases per year from 2013 to 2017.

The diagnosis was established after an extensive analysis of patients’ medical history and physical and neurological examination; it was based on the presence of clinical symptoms and signs and confirmed by at least one brain imaging technique. Isolated computed tomography scans were used in selected cases only (N = 9) during the first recruitment years. Magnetic resonance imaging was performed in 141 patients; in 72 to confirm computed tomography scan findings and in 69 patients, in the
later phase of research, as the only technique used. AIS was diagnosed based on the presence of neurological deficit of acute onset, seizures, or other signs of neonatal encephalopathy, and confirmed by neuroradiographic findings of parenchymal infarcts in cerebral arteries accordant with clinical manifestations. PAIS and CAIS were differentiated according to the definitions by Lynch (2).

CSVT was diagnosed after the neuroradiographic confirmation of a thrombus or flow interruption within cerebral veins or dural sinuses, together with clinical presentations of headache, seizure, lethargy, and focal or generalized neurologic deficit (38). Patients were included after a definite CSVT diagnosis by a neuroradiologist based on computed tomography as the first imaging exam for excluding a tumor, subdural hematoma, or abscess followed by magnetic resonance imaging combined with magnetic resonance angiography and venography as currently the best method for the confirmation of CSVT.

Written informed consent was obtained from all participants' parents and additionally from all children older than 12 years. The study was conducted in accordance with the tenets of the Declaration of Helsinki and approved by the Ethics Committee for Experimentation of the University of Zagreb Faculty of Pharmacy and Biochemistry (251-62-03-14-95), Ethics Committee of the University Hospital Centre Zagreb (02/21/JG), and Ethics Committee of the Children's Hospital Zagreb (01-26/18-14).

Molecular analysis

Genomic DNA was isolated from peripheral blood leukocytes and used for molecular analysis (Table 1). FV R506Q and HPA-1 were genotyped with CVD StripAssay® T and CVD StripAssay® A (ViennaLab Diagnostics, Vienna, Austria), respectively. Both tests were performed according to manufacturer's instructions: each DNA sample was amplified in two parallel multiplex polymerase chain reactions (PCR) using biotin-labeled primers. Amplification products were selectively hybridized to a test strip containing allele-specific oligonucleotide probes immobilized as an array of parallel lines. Bound PCR fragments were detected using streptavidin-alkaline phosphatase conjugate and color substrates. HPA-2 and HPA-3 were genotyped using previously described real-time PCR method based on TaqMan® technology on 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) (39). Three positive controls representing different genotypes for each polymorphism were included in each run as a quality control step (40).

Polymorphisms SELP S290N, V599L, and T715P were genotyped using PCR with specific primers followed by high res-

| TABLE 1. Genotyping methods for eight individual polymorphisms* |
|---------------------------------------------------------------|
| **Polymorphism** | **Method** | **Primer and minor groove binding probe sequences** | **Reference** |
| FV R506Q | multiplex PCR using biotin labeled primers, hybridization to ASO probes | n.a. | – |
| HPA-1 | multiplex PCR using biotin labeled primers, hybridization to ASO probes | n.a. | – |
| HPA-2 | real-time PCR method based on TaqMan® technology | F: 5′-GAGCTCTACCTGAAAGGCAATGA-3′ | (39) |
| | R: 5′-TGTGTGTAGCCAGACTGAGCTATCT-3′ | Pa: 5′-VIC-CTCCTGACGCCCCCACAC-NFQ-3′ | |
| | Pb: 5′-FAM-CTCCTGAGTGCCACAC-NFQ-3′ | | |
| HPA-3 | real-time PCR method based on TaqMan® technology | F: 5′-GGCCATCCCTTGCC-3′ | (39) |
| | R: 5′-GCGATCCCGCTTGTGA-3′ | Pa: 5′-VIC-CTGCCCATCCCCA-NFQ-3′ | |
| | Pb: 5′-FAM-CTGCCCATCCCCA-NFQ-3′ | | |
| SELP S290N | PCR with specific primers followed by high resolution melting analysis | F: 5′-CTCTGTTATTCTCTCGACGGTGC-3′ | (41) |
| SELP N562D | PCR with sequence specific primers | F: 5′-CTCCACCTGACATTCTTCTTGTA-3′ | (24) |
| SELP V599L | PCR with specific primers followed by high resolution melting analysis | F: 5′-TTGCCATCGCTTCTTGAGTAA-3′ | (41) |
| SELP T715P | PCR with specific primers followed by high resolution melting analysis | F: 5′-ATGAACGTCAACCTTCTGTG-3′ | (41) |

*Aso – allele-specific oligonucleotide; n.a. – not applicable; FV – factor V gene; HPA – human platelet antigens; SELP – selectin gene; PCR – polymerase chain reaction; NFQ – nonfluorescent quencher.
olution melting analysis on the LightCycler® 480 Real-Time PCR System (Roche Diagnostics, Mannheim, Germany) and results were analyzed using LightCycler® 480 Software (version 1.5; Roche Diagnostics) (41). Control samples of each genotype previously confirmed by sequencing were used as positive controls (24). SELP N562D was genotyped using the previously described PCR with sequence specific primers on the Applied Biosystems GeneAmp 2720 Thermal Cycler (24).

Statistical analysis

Normality of distribution was tested with the Shapiro-Wilk test (MedCalc software package version 9.3.2.0, Frank Schoonjans, the Netherlands). Continuous variables are expressed as medians and ranges. Descriptive analysis, Hardy-Weinberg equilibrium testing, and association analysis were performed with SNPassos (Catalan Institute of Oncology, Barcelona, Spain) (42,43), a web-based tool for the analysis of association studies that analyzes single SNPs by multiple inheritance models and multiple SNPs (haplotype analysis) based on logistic regression. The obtained genotyping results of FV R506Q, SELP polymorphisms, and HPAAs, SELP S290N/N562D/V599L/T715P, FV R506Q/SELP S290N/N562D/V599L/T715P, and HPA-1/-2/-3 haplotypes are expressed as frequencies. Hardy-Weinberg equilibrium was tested for each individual polymorphism in patients and controls. The most common combined genotypes were used as reference haplotypes in the analysis of haplotype association with disease. Associations of each individual polymorphism and haplotype with the disease risk were expressed as odds ratios (OR) with corresponding 95%

| TABLE 2. Characteristics of patients with ischemic stroke and the control group* |
|----------------------------------|---------------|----------------|---------------|-----------------|----------------|
| Group               | Number of participants | Male to female ratio | Age at diagnosis in years, median (range) | Age at testing in years, median (range) |
| IPS                 | 150             | 1.54            | 1.9 (0.0-18.0)        | 4.6 (0.0-18.0)        |
| AIS                 | 132             | 1.59            | 1.9 (0.0-18.0)        | 5.9 (0.0-18.0)        |
| PAIS                | 66              | 1.36            | 0.3 (0.0-12.0)        | 2.7 (0.0-18.0)        |
| CAIS                | 66              | 1.87            | 6.8 (0.4-18.0)        | 7.9 (0.4-18.0)        |
| CSVT                | 18              | 1.25            | 1.4 (0.0-12.8)        | 2.0 (0.0-15.4)        |
| Control group       | 150             | 1.54            | –                   | 7.0 (0.0-18.0)        |

*Dash – not applicable; IPS – ischemic pediatric stroke; AIS – arterial ischemic stroke; PAIS – perinatal arterial ischemic stroke; CAIS – childhood arterial ischemic stroke; CSVT – cerebral sinovenous thrombosis.

| TABLE 3. Individual polymorphisms in patients with ischemic pediatric stroke and its subtypes, and in the control group* |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|----------------|
| Polymorphism name | Patient group | Genotype | Genotype distribution in patient group, frequency | Genotype distribution in control group, frequency | OR (95% CI) | P     |
| FV R506Q          | PAIS           | GG       | 0.879                     | 0.967                     | 4.00 (1.26-12.74) | 0.017 |
|                   |                | GA       | 0.121                     | 0.033                     |                 |       |
|                   | CSVT           | aa       | 0.500                     | 0.733                     | 2.75 (1.02-7.42) | 0.048 |
|                   |                | ab       | 0.500                     | 0.247                     |                 |       |
|                   |                | bb       | 0.000                     | 0.020                     |                 |       |
| HPA-1              | IPS            | aa       | 0.411                     | 0.287                     | 0.58 (0.36-0.93) | 0.025 |
|                   |                | ab       | 0.411                     | 0.507                     |                 |       |
|                   |                | bb       | 0.178                     | 0.207                     |                 |       |
|                   | AIS            | aa       | 0.457                     | 0.287                     | 0.48 (0.29-0.78) | 0.003 |
|                   |                | ab       | 0.388                     | 0.507                     |                 |       |
|                   |                | bb       | 0.155                     | 0.207                     |                 |       |
|                   | PAIS           | aa       | 0.453                     | 0.287                     | 0.49 (0.26-0.89) | 0.020 |
|                   |                | ab       | 0.344                     | 0.507                     |                 |       |
|                   |                | bb       | 0.203                     | 0.207                     |                 |       |
|                   | CAIS           | aa       | 0.461                     | 0.287                     | 0.47 (0.26-0.86) | 0.014 |
|                   |                | ab       | 0.431                     | 0.507                     |                 |       |
|                   |                | bb       | 0.108                     | 0.207                     |                 |       |

*OR – odds ratio; CI – confidence intervals; IPS – ischemic pediatric stroke; FV – factor V gene; AIS – arterial ischemic stroke; PAIS – perinatal arterial ischemic stroke; HPA – human platelet antigen; CSVT – cerebral sinovenous thrombosis; CAIS – childhood arterial ischemic stroke.
confidence intervals (CI) by using a dominant model (a homozygous or heterozygous variant in comparison with the homozygous wild-type). A P value of <0.050 was considered significant.

RESULTS

All IPS subtypes were more prevalent in boys (Table 2). Genotype distributions of all investigated individual polymorphisms, both in cases and controls, were in Hardy-Weinberg equilibrium (results not shown), except HPA-3 polymorphism in children with PAIS (P = 0.035).

Among the examined individual polymorphisms, IPS was associated with only three polymorphisms: FV R506Q, HPA-1, and HPA-3 (Table 3). PAIS was significantly associated with FV R506Q; FV R506Q carriers had 4-fold increased risk for PAIS. Carriers of at least one HPA-1b allele

| Table 4. Human platelet antigen HPA-1/-2/-3 haplotype frequencies in patients with ischemic pediatric stroke and its subtypes, and the control group |
|-------------------------------------------------|
| **Group** | **HPA-1/-2/-3 haplotype** | **Haplotype frequency** | **OR (95% CI)** | **P** |
| IPS | HPA-1a2a3a | 0.429 | 1.00 (Ref) | Ref. |
| AIS | 0.446 | 1.00 (Ref) | Ref. |
| PAIS | 0.485 | 1.00 (Ref) | Ref. |
| CAIS | 0.429 | 1.00 (Ref) | Ref. |
| CSVT | 0.138 | 1.00 (Ref) | Ref. |
| Control group | 0.433 | – | – |
| IPS | HPA-1a2a3b | 0.301 | 0.89 (0.59-1.34) | 0.570 |
| AIS | 0.285 | 0.79 (0.51-1.21) | 0.270 |
| PAIS | 0.323 | 0.86 (0.52-1.41) | 0.540 |
| CAIS | 0.250 | 0.70 (0.39-1.24) | 0.220 |
| CSVT | 0.542 | 5.46 (1.51-19.76) | 0.011 |
| Control group | 0.351 | – | – |
| IPS | HPA-1b2a3a | 0.078 | 1.45 (0.64-3.27) | 0.370 |
| AIS | 0.079 | 1.32 (0.59-2.94) | 0.500 |
| PAIS | 0.071 | 1.10 (0.43-2.79) | 0.850 |
| CAIS | 0.086 | 1.54 (0.60-3.94) | 0.370 |
| CSVT | 0.137 | 7.00 (1.25-39.13) | 0.028 |
| Control group | 0.056 | – | – |
| IPS | HPA-1b2a3b | 0.073 | 1.06 (0.52-2.18) | 0.870 |
| AIS | 0.064 | 0.91 (0.43-1.92) | 0.810 |
| PAIS | 0.052 | 0.74 (0.28-1.95) | 0.550 |
| CAIS | 0.074 | 1.10 (0.44-2.75) | 0.840 |
| CSVT | 0.044 | 3.17 (0.39-25.93) | 0.280 |
| Control group | 0.060 | – | – |
| IPS | HPA-1a2b3a | 0.094 | 3.97 (1.29-12.17) | 0.016 |
| AIS | 0.104 | 4.46 (1.49-13.37) | 0.008 |
| PAIS | 0.056 | 2.15 (0.58-8.02) | 0.250 |
| CAIS | 0.147 | 6.76 (2.13-21.44) | 0.001 |
| CSVT | 0.016 | 4.19 (0.11-154.50) | 0.440 |
| Control group | 0.023 | – | – |
| IPS | HPA-1b2b3a | 0.016 | 0.57 (0.11-2.99) | 0.510 |
| AIS | 0.013 | 0.37 (0.05-2.58) | 0.320 |
| PAIS | 0.014 | 0.45 (0.05-3.73) | 0.460 |
| CAIS | 0.015 | 0.42 (0.04-3.99) | 0.450 |
| CSVT | 0.068 | 11.39 (1.39-92.95) | 0.024 |
| Control group | 0.027 | – | – |

*Dash – not applicable; Ref. – reference haplotype; HPA – human platelet antigen; OR – odds ratio; CI – confidence intervals; IPS – ischemic pediatric stroke; AIS – arterial ischemic stroke; PAIS – perinatal arterial ischemic stroke; CAIS – childhood arterial ischemic stroke; CSVT – cerebral sinovenous thrombosis.*
had a 2.75-fold increased risk for CSVT, while carriers of at least one HPA-3b allele had an approximately 2-fold lower risk for IPS and AIS, including both PAIS and CAIS. Carriers of HPA-3b allele (OR 6.43, 95% CI 0.83-50.00, P = 0.022; data not shown) had an increased risk for CSVT, but the result was not significant. However, additive model revealed a 2.23-fold increased risk for CSVT (95% CI 1.04-4.80, P = 0.034). Carriers of HPA-1a2b3a had a 4-fold increased risk for IPS and AIS, and 7-fold for CAIS. Interestingly, three different HPA-1/2/3 haplotypes showed a significant association with CSVT, resulting in five- to 11-fold increased risk: HPA-1a2a3b, HPA-1b2a3a, and HPA-1b2b3a. Haplotype HPA-1a2b3b was found in children with CSVT (0.054) and control group (0.050) only, but the result was not significant (OR 2.70, 95% CI 0.32-22.46, P = 0.360; data not shown) (Table 4).

**TABLE 5.** SELP S290N/N562D/V599L/T715P and FV R506Q/SELP S290N/N562D/V599L/T715P haplotype frequencies in patients with ischemic pediatric stroke and its subtypes, and the control group*

| Group | SELP S290N/N562D/V599L/T715P haplotype frequency | FV R506Q/SELP S290N/N562D/V599L/T715P haplotype frequency | OR (95% CI) | P |
|-------|--------------------------------------------------|--------------------------------------------------|------------|---|
| IPS   | SDVT                                             |                                                  | 0.396   | 1.00 (Ref.) | 0.405 | 1.00 (Ref.) | 0.267 | 1.18 (0.74-1.87) | 0.259 | 1.18 (0.73-1.89) | 0.490 | 0.96 (0.36-2.53) | 0.219 | 0.82 (0.30-2.28) | 0.240 | – |
| AIS   | SNVT                                             |                                                  | 0.387   | 1.00 (Ref.) | 0.379 | 1.00 (Ref.) | 0.271 | 1.19 (0.74-1.93) | 0.267 | 1.20 (0.74-1.93) | 0.460 | 0.96 (0.65-1.23) | 0.270 | 1.16 (0.64-2.09) | 0.360 | – |
| PAIS  |                                                  |                                                  | 0.413   | 1.00 (Ref.) | 0.419 | 1.00 (Ref.) | 0.266 | 1.18 (0.65-2.12) | 0.259 | 1.19 (0.66-2.16) | 0.590 | 0.96 (0.36-2.53) | 0.219 | 0.82 (0.30-2.28) | 0.240 | – |
| CAIS  |                                                  |                                                  | 0.381   | 1.00 (Ref.) | 0.386 | 1.00 (Ref.) | 0.271 | 1.19 (0.66-2.14) | 0.270 | 1.16 (0.64-2.09) | 0.560 | 0.96 (0.36-2.53) | 0.219 | 0.82 (0.30-2.28) | 0.240 | – |
| CSVT  |                                                  |                                                  | 0.445   | 1.00 (Ref.) | 0.448 | 1.00 (Ref.) | 0.405 | – – | 0.393 | – – | 0.930 | 0.96 (0.36-2.53) | 0.219 | 0.82 (0.30-2.28) | 0.240 | – |
| Control group |                                      |                                                  | 0.405   | – – | 0.393 | – – | 0.267 | 1.18 (0.74-1.87) | 0.259 | 1.18 (0.73-1.89) | 0.490 | 0.96 (0.36-2.53) | 0.219 | 0.82 (0.30-2.28) | 0.240 | – |

*Dash – not applicable; Ref. – reference haplotype; FV – factor V gene; SELP – P-selectin gene; OR – odds ratio; CI – confidence intervals; IPS – ischemic pediatric stroke; AIS – arterial ischemic stroke; PAIS – perinatal arterial ischemic stroke; CAIS – childhood arterial ischemic stroke; CSVT – cerebral sinovenous thrombosis.
Six SELP S290N/N562D/V599L/T715P and of FV R506Q/SELP S290N/N562D/V599L/T715P haplotypes were identified in all study groups. Although haplotype NDVT was more frequent in children with AIS and PAIS and least frequent in CAIS and AIS compared with control group, the result was not significant. Three rare haplotypes, NNLT, RNNLT, and QNDVT, were identified in AIS and controls only (results not shown). Haplotype QNDVT was more common in patients with PAIS than in control group (0.040 vs 0.002), but the result was not significant (OR 8.14, 95% CI 0.93-71.33, \(P=0.060\)) (Table 5).

**DISCUSSION**

This study demonstrated that various HPA genotypes and haplotypes were associated with IPS subtypes in a sample from Croatian child population and corroborated the hypothesis that different IPS subtypes did not share the same genetic risk factors.

The present study revealed an almost 3-fold increased risk for pediatric CSVT in carriers of at least one HPA-1b allele. This makes it the first study to our knowledge that found a positive association of HPA-1 and pediatric CSVT. The only study that investigated HPA-1 in pediatric CSVT to date reported more frequent HPA-1b allele-containing genotypes in CSVT than in both AIS and control group, but the results were not significant (20).

Consistent with previous findings on a moderate protective effect of HPA-3b allele for AIS and PAIS in Croatian population (9), the present study reported a 2-fold lower risk for IPS and CAIS, with the post-hoc calculated power of 0.51 for PAIS, 0.54 for CAIS, 0.59 for IPS, and 0.82 for AIS with a significance level of 0.050. On the contrary to this, we identified an unexpectedly high harmful effect of HPA-3b allele in CSVT, as opposed to its protective effect in AIS, but these findings did not reach significance. Although the sample size for CSVT is small, the polymorphism frequency is high. Post-hoc power analysis revealed the power of 0.44, meaning that additional 25 participants are needed to obtain the optimal power of 0.80.

HPA-1 and HPA-3 are both present on the most abundant glycoprotein IIb/IIa complex, which, by binding fibrinogen, is essential for platelet aggregation and thrombus formation. Recently, Ichord has reported that major risk factors for CSVT are acute head and neck infections as well as acute systemic illness (44), a conclusion similar to that reached in our study. As acute illness is linked to higher fibrinogen level, enhanced platelet-fibrinogen interactions are possible, leading to the formation of clots that are more stable and resistant to lysis.

A further analysis of HPA-1/-2/-3 haplotypes demonstrated for the first time that particular haplotypes were positively associated with both AIS and CSVT. Haplotype HPA-1a2b3a conferred an almost 7-fold increased risk for CAIS, but not for PAIS or CSVT, with a consequent increased risk for AIS and IPS. Moreover, compared with the effect of HPA-1 alone, two HPA-1b allele-containing haplotypes, HPA-1b2a3a and HPA-1b2b3a, conferred a three- to 4-fold increased risk for CSVT, respectively, whereas HPA-1a2a3b haplotype conferred a slightly lower risk.

Studies on HPAs in IPS are rare, provide contradictory results, and include only HPA-1 in differently defined pediatric populations (19-21). Literature search revealed an association of four specific HPA-1/-2/-3/-4 haplotypes with adult ischemic stroke and HPA-1b2b3a haplotype with coronary arterial disease, but the results are not comparable to our study due to differences in studied populations and HPAs included in haplotype analysis (17,45).

Concordant with the majority of studies performed in adults (32-37), the present study found no association between individual SELP polymorphisms and any IPS subtype. The post-hoc power analysis revealed very low power for all individual SELP polymorphisms in IPS. Although no significant association between SELP S290N/N562D/V599L/T715P haplotypes and adult ischemic stroke was identified in Caucasian population (34), the present study revealed an increased presence of the NDVT haplotype in children with AIS and PAIS, but not in children with CAIS and CSVT, pointing to its possible role in the etiology of PAIS only. The effect of NDVT haplotype may be explained by a previously reported association of SELP S290N/N562D/T715P haplotype NDT with increased soluble P-selectin plasma concentrations and the fact that SELP polymorphisms S290N and N562D are located within the SELP region important for the binding of P-selectins on leukocytes (26,46). As NNVT haplotype tends to decrease the risk for AIS, while NDVT haplotype tends to increase the risk for PAIS and AIS, it seems that N562D polymorphism is crucial for conferring the susceptibility to AIS.

The present study confirmed the association of FV R506Q with PAIS, which was previously established in a smaller study (8,46). Since the presence of multiple risk factors can have a synergistic effect (47), additional SELP haplotype
analysis also included FV R506Q, an established risk factor for IPS, which is located in the close proximity. Although the statistical significance was still not achieved, the inclusion of FV R506Q increased the risk for PAIS 4-fold in QNDVT carriers, as compared with NDVT haplotype alone, indicating a possible synergistic effect of SELP haplotype and FV R506Q.

The strength of this study is the inclusion of all IPS subtypes, including CSVT, enabling differentiation of their specific etiologies based on simultaneous identification of both harmful and protective genotype combinations. Moreover, the inclusion of haplotype analysis proved to be superior to the testing of single polymorphisms. To our knowledge, this is the only study to date investigating a possible association of SELP polymorphisms and HPA-1/-2/-3, SELP S290N/N562D/V599L/T715P and FV R506Q/SELP S290N/N562D/V599L/T715P haplotypes with IPS.

The study limitations include the relatively small sample of children with IPS, as association studies usually require large cohorts to minimize possible statistical biases in conclusions and to strengthen the study power. Certainly, the results obtained for only 18 CSVT cases should be taken with caution, but nevertheless, they present the preliminary evidence of the enhanced risk-inducing effect of the HPA-1/-2/-3 haplotypes for CSVT. Considering the aforementioned and the variable geographical and ethnical distribution of HPA genotypes (48), we cannot claim that the associations presented in this study can be applied to different populations or that the effect is limited to the Croatian population only, warranting further research of platelet gene polymorphisms in IPS subtypes.

To evaluate genotype-phenotype associations, the present study used the candidate gene approach rather than genome-wide approach because of the lower cost and high power of small-scale studies. Genome-wide association studies usually require extensive funding and have low power due to the number of independent tests performed (49). Our findings indicate that different IPS subtypes are characterized by specific sets of inherited thrombophilia risk factors and that there is a variable role of polymorphisms in the etiology of IPS subtypes. In the era of personalized medicine, it is crucial to better understand the clinical value and physiological implications of different genetic entities if we want to treat patients properly and reduce morbidity and mortality. We believe that future trials with sample sizes increased through international collaborations and extensive haplotype analysis would achieve a greater power to confirm the role of all the examined haplotypes in the etiology of IPS subtypes.

Funding part of the project “Genetic Polymorphisms and Ischemic Stroke in Children,” funded by the Croatian Science Foundation (HRZZ IP-2014-09-2047).

Ethical approval given by the Ethics Committee for Experimentation of the University of Zagreb Faculty of Pharmacy and Biochemistry (251-62-03-14-95), Ethics Committee of the University Hospital Centre Zagreb (02/21/JG), and Ethics Committee of the Children’s Hospital Zagreb (01-26/18-14).

Declaration of authorship AC, JJK, DCH, and RZ conceived and designed the study; AC, JJK, MP, and NB acquired the data; AC, DCH, MM, VB, and RZ analyzed and interpreted the data; AC and RZ drafted the manuscript; all authors critically revised the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.clinicaltrials.gov (available on request from the corresponding author) and declare: no support from any organization of the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Raju TNK, Nelson KB, Ferriero D, Lynch JK. Ischemic perinatal stroke: summary of a workshop sponsored by the National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke. Pediatrics. 2007;120:609-16. doi:10.1542/peds.2007-0336
2. Lynch JK. Cerebrovascular disorders in children. Curr Neurol Neurosci Rep. 2004;4:129-38. doi:10.1007/s11910-004-0027-3
3. Tsze DS, Valente JH. Pediatric stroke: a review. Emerg Med Int. 2011;2011:1-10. doi:10.1155/2011/734506
4. Kenet G, Lüskhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: A systematic review and meta-analysis of observational studies. Circulation. 2010;121:1838-47. doi:10.1161/CIRCULATIONAHA.109.913673
5. Zadro R, Coen Herak D. Inherited prothrombotic risk factors in children with first ischemic stroke. Biochem Med (Zagreb). 2012;22:298-310. doi:10.11613/BM.2012.033
6. Kirton A, DeVeber G. Paediatric stroke: pressing issues and promising directions. Lancet Neurol. 2015;14:92-102. doi:10.1016/S1474-4422(14)70227-3
7. Zoller B, Holm J, Dahlbäck B. Resistance to activated protein C due to a factor V gene mutation. Trends Cardiovasc Med. 1996;6:45-53. doi:10.1016/1529-3279(96)00013-0
Croat Med J. 2020;61:18-27

8 Capecchi M, Abbatistia M, Martinelli I. Cerebral venous sinus thrombosis. J Thromb Haemost. 2018;16:1918-31. Medline:29923367 doi:10.1111/jth.14210

9 Coen Herak D, Lenicek Krleza J, Radic Antolic M, Horvat I, Djuranovic V, Zrniski Topic R, et al. Association of polymorphisms in coagulation factor genes and enzymes of homocysteine metabolism with arterial ischemic stroke in children. Clin Appl Thromb Hemost. 2017;23:1042-51. Medline:28301901 doi:10.1177/1076029616672584

10 Kirton A, Armstrong-Wells J, Chang T, DeVeber G, Rivkin MJ, Faber CG, Lodder J, Kessels F, troost J. Thrombin generation from a comprehensive meta-analysis. Int J Stroke. 2017;10:46-70. Medline:2800499 doi:10.1160/thoKeAHA.107.50722

11 Wiklund A, Pihlajaniemi T, Barreda L, et al. Polymorphisms in platelet glycoprotein 1bα and factor Vii and relationship between P-selectin polymorphisms and thrombosis in antiphospholipid syndrome: a pilot case-control study. Turk J Haematol. 2014;31:357-62. Medline:2554165 doi:10.4274/tjh.2013.0091

12 Ay C, Jungbauer LV, Kaider A, Koder S, Panzer S, Pabinger I, et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. Thromb Haemost. 2008;99:899-904. Medline:18449419 doi:10.1160/thoKe11-0672

13 Santoso S. Human platelet alloantigens. Transfus Apher Sci. 2003;28:227-36. Medline:12725948 doi:10.1111/j.1365-2076.2003.02803.x

14 Curtis BR, McFarland JG. Human platelet antigens - 2013. Vox Sang. 2014;106:93-102. Medline:24102564 doi:10.1111/vox.12085

15 Liu H, Wang Y, Zheng J, Li G, Chen T, Lei J, et al. Platelet glycoprotein gene la (CBOT7, HPA-3, and Ibα VNTR polymorphisms are associated with increased ischemic stroke risk: evidence from a comprehensive meta-analysis. Int J Stroke. 2012;17:46-70. Medline:28049990 doi:10.11177/1747493018672085

16 Maguire JM, Thakkinstain A, Sturm J, Levi C, Linz C, Parsons M, et al. Polymorphisms in platelet glycoprotein Ibα and factor VII and risk of ischemic stroke. Stroke. 2008;39:1710-6. Medline:18403734 doi:10.1161/STROKEAHA.107.507228

17 Saldí S, Mahjoub T, Slamia LB, Ammou SB, Al-Subaie AM, Almawi WY. Polymorphisms of the human platelet alloantigens HPA-1, HPA-2, HPA-3, and HPA-4 in ischemic stroke. Am J Hematol. 2008;83:570-3. Medline:18383324 doi:10.1002/ajh.21171

18 Duan H, Cai Y, Sun X. Platelet glycoprotein Ibβ/IIa polymorphism HPA-3 b/b is associated with increased risk of ischemic stroke in patients under 60 years of age. MedSciMonit. 2012;18:19-24. Medline:22207115 doi:10.12659/MSM822195

19 Biswas A, Tiwari AK, Ranjan R, Meena A, Akhter MS, Yadav BK, et al. Prothrombotic polymorphisms, mutations, and their association with pediatric non-cardioembolic stroke in Asian-Indian patients. Ann Hematol. 2009;88:473-8. Medline:18836720 doi:10.1007/s00277-009-0613-6

20 Miller SP, Wu YW, Lee J, Lammer EJ, Iovannisci DM, Glidden DV, et al. Candidate gene polymorphisms do not differ between newborns with stroke and normal controls. Stroke. 2006;37:2678-83. Medline:17008620 doi:10.1160/1.STR.0000244810.91105.c9

21 Comitopoulou A, Platokouki H, Kapsimali Z, Pergantou H, Adamtziki E, Aronis S. Mutations and polymorphisms in genes affecting hemostasis proteins and homocysteine metabolism in children with arterial ischemic stroke. Cerebrovasc Dis. 2006;22:13-20. Medline:16657932 doi:10.1159/000092332

22 Andre P, P-selectin in haemostasis. Br J Haematol. 2004;126:298-306. Medline:15257701 doi:10.1111/j.1365-2457.2004.05032.x

23 McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015;107:331-9. Medline:25994174 doi:10.1093/cvr/cv415

24 Bugeux P, Vosberg M, Entellmann M, Jahn J, Katus HA, Klüter H. Polymorphisms in the P-selectin (CD62P) and P-selectin glycoprotein ligand-1 (PSGL-1) genes and coronary heart disease. Clin Chem Lab Med. 2004;42:997-1004. Medline:15497463 doi:10.1515/CCLM.2004.202

25 Kappelmayer J, Nagy B. The interaction of selectins and PSGL-1 as a key component in thrombus formation and cancer progression. BioMed Res Int. 2017;2017:1-18. Medline:28680883 doi:10.1155/2017/6138145

26 Ay C, Jungbauer LV, Kaider A, Koder S, Panzer S, Pabinger I, et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. Thromb Haemost. 2008;99:899-904. Medline:18449419 doi:10.1160/thoKe11-0672

27 Alpay N, Hançer VS, Erer B, Inanı M, Diz Küçükayakya R. The relationship between P-selectin polymorphisms and thrombosis in antiphospholipid syndrome: a pilot case-control study. Turk J Haematol. 2014;31:357-62. Medline:25541651 doi:10.4274/tjh.2013.0091

28 Kee F, Morrison C, Evans AE, McCrum E, McMaster D, Dallongeville J, et al. Polymorphisms of the P-selectin gene and risk of myocardial infarction in men and women in the ECTIM extension study. Heart. 2000;84:548-52. Medline:11040019 doi:10.1136/heart.84.5.548

29 Herrmann SM, Ricard S, Nican V, Mallet C, Evans A, Ruidavets JB, et al. The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. Hum Mol Genet. 1998;7:1277-84. Medline:9668170 doi:10.1093/hmg/7.8.1277

30 Reiner AP, Carlson Cs, Thyagarajan B, Rieder MJ, Polak JF, Siscovick DS, et al. Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-American young adults the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb Vasc Biol. 2008;28:1549-55. Medline:18535285 doi:10.1161/ATVBAHA.108.169532

31 Carter AM, Anagnostopoulou K, Mansfield MW, Grant PJ. Soluble P-selectin levels, P-selectin polymorphisms and cardiovascular disease. J Thromb Haemost. 2003;1:1718-23. Medline:12911583
doi:10.1046/j.1538-7836.2003.00312.x
32 Zee RYL, Cook NR, Cheng S, Reynolds R, Erlich HA, Lindpaintner K, et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet. 2003;13:389-96. Medline:14681304 doi:10.1093/hmg/ddh039
33 Wei Y-S, Lan Y, Huang R-Y, Liu Y-G, Xu Q-Q, et al. Association of the single-nucleotide polymorphism and haplotype of the P-selectin gene with ischemic stroke. J Thromb Thrombolysis. 2009;27:75-81. Medline:18034324 doi:10.1093/hmg/ddh039
34 Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Boerwinkle E. Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2007;195:e76-82. Medline:17420019 doi:10.1016/j.atherosclerosis.2007.03.007
35 Ferrari J, Rieger s, endler G, Greisenegger s, Funk M, scholze t, et al. the thr715Pro polymorphism of the P-selectin gene is not associated with ischemic stroke risk. stroke. 2007;38:395-7. Medline:1720468 doi:10.1161/01.STR.0000254475.43533.dd
36 Tao L, Changfu W, Linyun L, Bing M, Xiaohui H. Correlations of platelet-leukocyte aggregates with P-selectin s290N and P-selectin glycoprotein ligand-1 M62i genetic polymorphisms in patients with acute ischemic stroke. J Neurol Sci. 2016;367:95-100. Medline:27423570 doi:10.1016/j.jns.2016.05.046
37 Schmalbach B, Stepanow O, Jochens A, Riedel C, Deuschl G, Kuhlenbäumer G. Determinants of platelet-leukocyte aggregation and platelet activation in stroke. Cerebrovasc Dis. 2015;39:176-80. Medline:25720421 doi:10.1159/000375396
38 Sèbire G, Fullerton H, Riou E, DeVeber G. Towards the definition of cerebral arteriopathies of childhood. Curr Opin Pediatr. 2004;16:617-22. Medline:15548922 doi:10.1097/01.mop.0000144441.29699.20
39 Ficko T, Galvani V, Rupreht R, Dovc T, Rozman P. Real-time PCR genotyping of human platelet alloantigens HPA-1, HPA-2, HPA-3 and HPA-5 is superior to the standard PCR-SSP method. Transfus Med. 2004;14:425-32. Medline:15569237 doi:10.1111/j.1365-3148.2004.00538.x
40 Bein G, Hackstein H, Klüter H. DNA typing of human platelet antigen systems 1, 2 and 3 in B-lymphoblastoid cell lines of the International Histocompatibility Workshop. Tissue Antigens. 1997;49:443-7. Medline:9174135 doi:10.1111/j.1399-0039.1997.tb02777.x
41 Ceri A, Pavic M, Horvat I, Radic Antolic M, Zadro R. Development and validation of a rapid method for genotyping three P-selectin gene polymorphisms based on high resolution melting analysis. J Clin Lab Anal. 2019;33:e22698. Medline:30350887 doi:10.1002/jcla.22698
42 Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928-9. Medline:16720584 doi:10.1093/bioinformatics/btl268
43 Institut Catalá D’Oncologia. SNPStats: your web tool for SNP analysis. 2006. Available from: https://www.snpstats.net/start.htm. Accessed: January 21, 2020.
44 Ichord R. Cerebral sinovenous thrombosis. Front Pediatr. 2017;5:163. Medline:28798906 doi:10.3389/fped.2017.00163
45 Abboud N, Ghazouani L, Ben-Hadj-Khalifa S, Anabi F, Addad F, Khalfallah A, et al. Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease. J Thromb Thrombolysis. 2010;29:409-15. Medline:19562259 doi:10.1002/s11239-009-0368-5
46 Ruchaud-Sparagano M-H, Malaud e, Gayet O, Chignier E, Buckland R, McGregor JL. Mapping the epitope of a functional P-selectin monoclonal antibody (LYP20) to a short complement-like repeat (SCR 4) domain: use of human-mouse chimera and homologue-replacement mutagenesis. Biochem J. 1998;332:309-14. Medline:9601057 doi:10.1042/bj3320309
47 Mackay Mt, Wiznitzer M, Benedict SL, Lee KJ, DeVeber GA, Ganesan V. Arterial ischemic stroke risk factors: The international pediatric stroke study. Ann Neurol. 2011;69:130-40. Medline:21280083 doi:10.1002/ana.22224
48 Pavic M, Zadro R, Coen Herak D, Radic Antolic M, Dodig S. Gene frequencies of platelet-specific antigens in Croatian population. Transfus Med. 2010;20:73-7. Medline:19778317 doi:10.1111/j.1365-3148.2009.00971.x
49 Amos W, Driscoll E, Hoffman JL. Candidate genes versus genome-wide associations: which are better for detecting genetic susceptibility to infectious disease? Proc Biol Sci. 2011;278:1183-8. Medline:20926441 doi:10.1098/rspb.2010.1920